EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Hypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma

Nancy Y Lee iD, Eric J Sherman iD, HeiKo Schöder iD, Rick Wray iD, Jay O Boyle, Bhuvanesh Singh, Milan Grkovski iD, Ramesh Paudyal iD, Louise Cunningham, Zhigang Zhang, Vaios Hatzoglou, Nora Katabi und 30 weitere

Journal of Clinical Oncology · 10.03.2024 · 42 (8) · 940-950

DOI: 10.1200/jco.23.01308 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.03.2024. Verfasst von Nancy Y Lee und 41 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Papillomavirus Infections, Oropharyngeal Neoplasms, Carcinoma. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Standard curative-intent chemoradiotherapy for human papillomavirus (HPV)–related oropharyngeal carcinoma results in significant toxicity. Since hypoxic tumors are radioresistant, we posited that the aerobic state of a tumor could identify patients eligible for de-escalation of chemoradiotherapy while maintaining treatment efficacy. METHODS We enrolled patients with HPV-related oropharyngeal carcinoma to receive de-escalated definitive chemoradiotherapy in a phase II study (ClinicalTrials.gov identifier: NCT03323463 ). Patients first underwent surgical removal of disease at their primary site, but not of gross disease in the neck. A baseline 18 F-fluoromisonidazole positron emission tomography scan was used to measure tumor hypoxia and was repeated 1-2 weeks intratreatment. Patients with nonhypoxic tumors received 30 Gy (3 weeks) with chemotherapy, whereas those with hypoxic tumors received standard chemoradiotherapy to 70 Gy (7 weeks). The primary objective was achieving a 2-year locoregional control (LRC) of 95% with a 7% noninferiority margin. RESULTS One hundred fifty-eight patients with T0-2/N1-N2c were enrolled, of which 152 patients were eligible for analyses. Of these, 128 patients met criteria for 30 Gy and 24 patients received 70 Gy. The 2-year LRC was 94.7% (95% CI, 89.8 to 97.7), meeting our primary objective. With a median follow-up time of 38.3 (range, 22.1-58.4) months, the 2-year progression-free survival (PFS) and overall survival (OS) rates were 94% and 100%, respectively, for the 30-Gy cohort. The 70-Gy cohort had similar 2-year PFS and OS rates at 96% and 96%, respectively. Acute grade 3-4 adverse events were more common in 70 Gy versus 30 Gy (58.3% v 32%; P = .02). Late grade 3-4 adverse events only occurred in the 70-Gy cohort, in which 4.5% complained of late dysphagia. CONCLUSION Tumor hypoxia is a promising approach to direct dosing of curative-intent chemoradiotherapy for HPV-related carcinomas with preserved efficacy and substantially reduced toxicity that requires further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsOropharyngeal NeoplasmsCarcinomaHumansHuman Papillomavirus VirusesChemoradiotherapyHypoxia

Autor:innen und Institutionen

  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.

ORCID-Profile: Nancy Y Lee, Eric J Sherman, HeiKo Schöder, Rick Wray, Milan Grkovski, Ramesh Paudyal, Brandon S Imber, Yao Yu, Kaveh Zakeri, Sean M McBride, Jung J Kang, C Jillian Tsai, Jatin P Shah, Ian Ganly, Luc G T Morris, Alan L Ho, Simon N Powell, Bob T Li, Luis A Diaz, Nadeem Riaz

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Lee, N. Y., Sherman, E. J., Schöder, H., Wray, R., Boyle, J. O., Singh, B., Grkovski, M., Paudyal, R., Cunningham, L., Zhang, Z., Hatzoglou, V., Katabi, N., Diplas, B. H., Han, J., Imber, B. S., Pham, K., Yu, Y., Zakeri, K., McBride, S. M., …, & Riaz, N. (2024). Hypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma. Journal of Clinical Oncology, 42(8), 940-950. https://doi.org/10.1200/jco.23.01308

Vancouver

Lee NY, Sherman EJ, Schöder H, Wray R, Boyle JO, Singh B, et al. Hypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma. Journal of Clinical Oncology. 2024;42(8):940-950. doi:10.1200/jco.23.01308

BibTeX
@article{Lee2024,
  author = {Lee, Nancy Y and Sherman, Eric J and Schöder, HeiKo and Wray, Rick and Boyle, Jay O and Singh, Bhuvanesh and Grkovski, Milan and Paudyal, Ramesh and Cunningham, Louise and Zhang, Zhigang and Hatzoglou, Vaios and Katabi, Nora and Diplas, Bill H and Han, James and Imber, Brandon S and Pham, Khoi and Yu, Yao and Zakeri, Kaveh and McBride, Sean M and Kang, Jung J and Tsai, C Jillian and Chen, Linda C and Gelblum, Daphna Y and Shah, Jatin P and Ganly, Ian and Cohen, Marc A and Cracchiolo, Jennifer R and Morris, Luc G T and Dunn, Lara A and Michel, Loren S and Fetten, James V and Kripani, Anuja and Pfister, David G and Ho, Alan L and Shukla-Dave, Amita and Humm, John L and Powell, Simon N and Li, Bob T and Reis-Filho, Jorge S and Diaz, Luis A and Wong, Richard J and Riaz, Nadeem},
  title = {Hypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {8},
  pages = {940--950},
  doi = {10.1200/jco.23.01308}
}
Kostenlos starten →